Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
1. AMLX presented new trial data on avexitide at ENDO 2025. 2. Avexitide reduced moderate to severe hypoglycemic events by 64% in Phase 2b. 3. LUCIDITY trial aims for a 2026 result on avexitide's efficacy for PBH. 4. Consistent dose-dependent reductions were observed across previous trials. 5. Stock price increased by 7.55% to $8.26 following the announcement.